Version for print Main / Articles / Dyslipidemia: a role of hereditary and secondary factors

Dyslipidemia: a role of hereditary and secondary factors

Scopus

Abstract

DOI: 10.32364/2587-6821-2026-10-1-4

Dyslipidemia: a role of hereditary and secondary factors

E.A. Shumeyko, O.V. Senatorova

Tyumen State Medical University, Tyumen, Russian Federation

Dyslipidemia is defined as a deviation of at least one lipid profile parameter from normal values. In different populations, prevalence of dyslipidemia ranges from 33.8% to 76.7% of the surveyed cohort. The aim of this work is to analyze hereditary and secondary factors that cause certain manifestations of dyslipidemia. The obesity epidemic observed in recent decades is accompanied by impaired lipid metabolism and changes in the plasma lipid profile indicating increased atherogenic potential leading to vascular damage and increased cardiovascular morbidity. Increasingly diagnosed obesity and increasing incidence of dyslipidemia in adolescents indicate the likelihood of premature cardiovascular diseases. The structure of dyslipidemia is complex and it can include a variety of causes and manifestations. Dyslipidemias are generally divided into familial/primary dyslipidemias and acquired/secondary dyslipidemias, that is, those associated with predisposing diseases and pathological conditions, as well as use of certain medications. Elevated levels of cholesterol, triglycerides, low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), and high-density lipoprotein (HDL) are the most common in clinical practice. Each nosological variant of dyslipidemia has its own distinctive features which are highlighted in the review.

Keywords: dyslipidemia, cholesterol, atherosclerosis, lipoproteins, triglycerides, chylomicrons, low-density lipoproteins.

For citation: Shumeyko E.A., Senatorova O.V. Dyslipidemia: a role of hereditary and secondary factors. Russian Medical Inquiry. 2026;10(1):26–32 (in Russ.). DOI: 10.32364/2587-6821-2026-10-1-4

Дислипидемия: роль наследственных и вторичных факторов

About the authors:

Elena A. Shumeyko — C. Sc. (Med.), Teaching Assistant of the Department of Mobilization Training of Healthcare and Disaster Medicine with the Basics of Military Training, Tyumen State Medical University; 54, Odesskaya str., Tyumen, 625023, Russian Federation; ORCID iD 0009-0002-3338-2220

Olga V. Senatorova — C. Sc. (Med.), Assistant Professor of the Department of Pediatric Diseases and Polyclinic Pediatrics, Institute of Motherhood and Childhood, Tyumen State Medical University; 54, Odesskaya str., Tyumen, 625023, Russian Federation; ORCID iD 0000-0001-7450-2888

Contact information: Elena A. Shumeyko, e-mail: shumeiko1123@gmail.com

There is no conflict of interest.

Received 26.12.2025.

Revised 26.01.2026.

Accepted 16.02.2026.

References

1. Li Z., Zhu G., Chen G. et al. Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007-2018. Lipids Health Dis. 2022;21(1):111. DOI: 10.1186/s12944-022-01721-y 2. Lu Y., Zhang H., Lu J. et al. Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China. JAMA Netw Open. 2021;4(9):e2127573. DOI: 10.1001/jamanetworkopen.2021.27573 3. Islam M.T., Samad Talha M.T.U., Shafiq S.S. et al. Prevalence, pattern, and correlates of dyslipidemia in Bangladeshi individuals. J Clin Lipidol. 2023;17(6):788–799. DOI: 10.1016/j.jacl.2023.09.007 4. Вилков В.Г., Шальнова С.А. Тридцатилетняя динамика распространенности кардиометаболических факторов риска в популяциях Российской Федерации и Соединенных Штатов Америки. Кардиоваскулярная терапия и профилактика. 2022;21(8):34–39. DOI: 10.15829/1728-8800-2022-3304Vilkov V.G., Shalnova S.A. Thirty-year dynamics of the prevalence of cardiometabolic risk factors in the populations of the Russian Federation and the United States of America. Cardiovascular Therapy and Prevention. 2022;21(8):34–39 (in Russ.). DOI: 10.15829/1728-8800-2022-3304 5. Andrades C.D.S., Poletti V.V., Closs V.E. et al. Prevalence of dyslipidemia, atherogenic and cardiovascular risk in overweight and obese adolescents. Rev Paul Pediatr. 2023;41:e2021312. DOI: 10.1590/1984-0462/2023/41/2021312 6. Драпкина О.М., Имаева А.Э., Куценко В.А. и др. Дислипидемии в Российской Федерации: популяционные данные, ассоциации с факторами риска. Кардиоваскулярная терапия и профилактика. 2023;22(8S):92–104. DOI: 10.15829/1728-8800-2023-3791Drapkina O.M., Imaeva A.E., Kutsenko V.A. et al. Dyslipidemias in the Russian Federation: population data, associations with risk factors. Cardiovascular Therapy and Prevention. 2023;22(8S):92–104 (in Russ.). DOI: 10.15829/1728-8800-2023-3791 7. Huang J.X.F., Yousaf A., Moon J. et al. Recent Advances in the Management of Dyslipidemia: A Systematic Review. Cureus. 2025;17(3):e81034. DOI: 10.7759/cureus.81034 8. Mainieri F., La Bella S., Chiarelli F. Hyperlipidemia and cardiovascular risk in children and adolescents. Biomedicines. 2023;11:809. DOI: 10.3390/biomedicines11030809 9. Regmi M., Rehman A. Familial Hyperchylomicronemia Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. 10. Nohara A., Tada H., Ogura M. et al. Homozygous Familial Hypercholesterolemia. J Atheroscler Thromb. 2021;28(7):665–678. DOI: 10.5551/jat.RV17050 11. Blom D.J., Marais A.D., Raal F.J. Homozygous Familial Hypercholesterolemia Treatment: New Developments. Curr Atheroscler Rep. 2025;27(1):22. DOI: 10.1007/s11883-024-01269-5 12. Santos R.D., Wiegman A., Caprio S. et al. Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA Pediatr. 2024;178(3):283–293. DOI: 10.1001/jamapediatrics.2023.6477 13. Tada H., Harada-Shiba M. Assessments of Atherosclerosis and Treatment Strategies for Heterozygous Familial Hypercholesterolemia. J Atheroscler Thromb. 2025;32(10):1211–1219. DOI: 10.5551/jat.RV22041 14. Liu H., Peng D. Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism. Endocr Connect. 2022;11(2):e210002. DOI: 10.1530/EC-21-0002 15. Su X., Chen X., Peng H. et al. Novel insights into the pathological development of dyslipidemia in patients with hypothyroidism. Bosn J Basic Med Sci. 2022;22(3):326–339. DOI: 10.17305/bjbms.2021.6606 16. Martin S.S., Daya N., Lutsey P.L. et al. Thyroid function, cardiovascular risk factors, and incident atherosclerotic cardiovascular disease: The atherosclerosis risk in communities (ARIC) study. J Clin Endocrinol Metab. 2017;102(9):3306–3315. DOI: 10.1210/jc.2017-00986 17. Luxia L., Jingfang L., Songbo F. et al. Correlation between serum TSH levels within normal range and serum lipid profile. Horm Metab Res. 2021;53(1):32–40. DOI: 10.1055/a-1191-7953 18. Gao M., Cao L., Wang H. et al. Correlation between subclinical hypothyroidism and dyslipidemia in women in northeast China. Acta Endocrinol (Buchar). 2021;17(2):282–285. DOI: 10.4183/aeb.2021.282 19. Van Vliet N.A., Bos M.M., Thesing C.S. et al. Higher thyrotropin leads to unfavorable lipid profile and somewhat higher cardiovascular disease risk: evidence from multi-cohort Mendelian randomization and metabolomic profiling. BMC Med. 2021;19(1):266. DOI: 10.1186/s12916-021-02130-1 20. Kane J.P., Pullinger C.R., Goldfine I.D. et al. Dyslipidemia and diabetes mellitus: Role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus. Curr Opin Pharmacol. 2021;61:21–27. DOI: 10.1016/j.coph.2021.08.013 21. Kalra S., Raizada N. Dyslipidemia in diabetes. Indian Heart J. 2024;76(Suppl 1):S80–S82. DOI: 10.1016/j.ihj.2023.11.002 22. Karakasis P., Theofilis P., Patoulias D. et al. Diabetes-Driven Atherosclerosis: Updated Mechanistic Insights and Novel Therapeutic Strategies. Int J Mol Sci. 2025;26(5):2196. DOI: 10.3390/ijms26052196 23. Liu J., Kang J., Liang P. et al. The association between triglyceride-glucose index and all-cause/cardiovascular mortality in patients with different glucose metabolism statuses. Cardiovasc Diabetol. 2025;24(1):367. DOI: 10.1186/s12933-025-02826-1 24. Ikeda I., Igarashi R., Fujihara K. et al. Cross-sectional and Longitudinal Associations Between Family History of Type 2 Diabetes Mellitus, Hypertension, and Dyslipidemia and Their Prevalence and Incidence: Toranomon Hospital Health Management Center Study (TOPICS24). Mayo Clin Proc. 2025;100(8):1370–1382. DOI: 10.1016/j.mayocp.2024.10.020 25. Kim J.Y., Chung S.M., Kim N.H. Managing dyslipidemia in chronic kidney disease: a comprehensive overview of evidence and recommendations. Korean J Intern Med. 2025;40(6):876–889. DOI: 10.3904/kjim.2025.099 26. Zhu D., Judge P.K., Wanner C. et al. The prevention and management of chronic kidney disease among patients with metabolic syndrome. Kidney Int. 2025;107(5):816–824. DOI: 10.1016/j.kint.2024.12.021 27. Yoshida Y., Hagiwara Y., Ito M. et al. Association of Obesity, Visceral Fat Accumulation, and Dyslipidemia with the Risk of Chronic Kidney Disease. Intern Med. 2025;64(19):2823–2828. DOI: 10.2169/internalmedicine.4613-24 28. Xu W., Yau Y.K., Pan Y. et al. Effectiveness and safety of using statin therapy for the primary prevention of cardiovascular diseases in older patients with chronic kidney disease who are hypercholesterolemic: a target trial emulation study. Lancet Healthy Longev. 2025;6(3):100683. DOI: 10.1016/j.lanhl.2025.100683 29. Tu Q.M., Jin H.M., Yang X.H. Lipid abnormality in diabetic kidney disease and potential treatment advancements. Front Endocrinol (Lausanne). 2025;16:1503711. DOI: 10.3389/fendo.2025.1503711 30. Folestad E., Mehlem A., Ning F.C. et al. Vascular endothelial growth factor B-mediated fatty acid flux in the adipose-kidney axis contributes to lipotoxicity in diabetic kidney disease. Kidney Int. 2025;107(3):492–507. DOI: 10.1016/j.kint.2024.11.026 31. Richie R.C. Steatotic Liver Diseases (SLDs): A Review. J Insur Med. 2025;52(3):128–136. DOI: 10.17849/insm-52-3-1-9.2 32. Zisis M., Chondrogianni M.E., Androutsakos T. et al. Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment. Biomolecules. 2025;15(3):324. DOI: 10.3390/biom15030324 33. Rini S.S., Wibawa I.DN. Evaluation and Management of Chronic Cholestatic Liver Diseases. Middle East J Dig Dis. 2023;15(3):148–155. DOI: 10.34172/mejdd.2023.336 34. Zheng L., Tian S., Yang C. et al. Hypercholesterolemia Is Associated With Dysregulation of Lipid Metabolism and Poor Prognosis in Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2024;22(6):1265–1274.e19. DOI: 10.1016/j.cgh.2024.01.039 35. Huang H., Li J., Chen T. et al. The correlation between lipids and intrahepatic cholestasis syndrome during pregnancy. J Obstet Gynaecol. 2024;44(1):2369929. DOI: 10.1080/01443615.2024.2369929 36. Пшеничникова И.И., Пупыкина В.В., Пшеничникова А.Д. и др. Потребление алкогольных напитков и дислипидемия у детей и подростков. Педиатрия. Consilium Medicum. 2024;3:271–273. DOI: 10.26442/26586630.2024.3.202928Pshenichnikova I.I., Pupykina V.V., Pshenichnikova A.D. et al. Alcohol consumption and dyslipidemia in children and adolescents. Pediatrics. Consilium Medicum. 2024;3:271–273 (in Russ.). DOI: 10.26442/26586630.2024.3.202928 37. Kampire M.G., Hakizimana J.C., Mucumbitsi J. et al. Pathophysiological Consequences Associated with Hormonal Contraceptives Use in Sub-Saharan Africa: A Scoping Review. Open Access J Contracept. 2025;16:171–187. DOI: 10.2147/OAJC.S563680 38. Tang Z., Guan J., Mao J.H. et al. Quantitative risk-benefit profiles of oral contraceptives, insulin sensitizers and antiandrogens for women with polycystic ovary syndrome: A model-based meta-analysis. Eur J Pharm Sci. 2023;190:106577. DOI: 10.1016/j.ejps.2023.106577 39. Battipaglia C., Genazzani A.D., Nappi R.E. et al. Insights on estetrol, the native estrogen: from contraception to hormone replacement therapy. Minerva Obstet Gynecol. 2024;76(6):590–603. DOI: 10.23736/S2724-606X.24.05594-5 40. Чазова И.Е., Мычка В.Б. Возможно ли назначение мочегонных препаратов у пациентов с метаболическим синдромом и сахарным диабетом? Consilium Medicum. 2004;6(5):341–344.Chazova I.E., Michka V.B. Is it possible to prescribe diuretics to patients with metabolic syndrome and diabetes mellitus? Consilium Medicum. 2004;6(5):341–344 (in Russ.).

This work is licensed under a Creative Commons «Attribution» 4.0 License.

Read the article in PDF in Russian

Safety and pattern of cardioselective be...

1071

Factors influencing the level of NT-proB...

2066

All articles